Kornimate/medical-research-clean huggingface dataset:
frailty and complexity among home service recipients

Conditions: Frail Elderly Syndrome

Summary: the purpose of the study is to develop frailty and complexity computation algorithms based on the french version of the interrai-hc and, in doing so, to provide homecare nurses with valid and reliable screening tools for their routine practice. by relying on a prospective observational case-control longitudinal study, the study intends to assess the predictive validity of the proposed indices with respect to undesirable health outcomes. repeated measurement occasions, separated by 6-month intervals, will also allow for estimation of intra-individual change in frailty and complexity. in the study, elders living in the community and aged 65 or older are the target population, and three samples will be considered based on the a priori risks of adverse outcomes (case 1: formal home service recipients; case 2: formal home care recipients; control: free of formal home care or service). these groups will be compared on the observed rates of frailty and complexity and on their evolution over time. results will allow for identification of subgroups of the aged population for whom early screening of frailty and complexity appears most relevant. based on the findings, practice guideline will be proposed. they will entail the interpretation of the scores and recommendations for mounting adapted preventive strategies. finally, the study will contribute to enhancing knowledge on the relation between frailty, a well-known concept in gerontology, and complexity, a concept increasingly referred to in the care literature but that still deserves operational and consensual definitions.


Eligibility criteria:
inclusion criteria: * living in the community (private home) * resident of canton geneva, switzerland * ability to hold a conversation in french (expression, comprehension) * oriented in time and space exclusion criteria: * living in hospital / nursing home * not resident of canton geneva, switzerland * not fluent in french * disoriented in time and space * person under tutorship

Keywords: home care services geriatric assessment aging frailty complexity nursing
screening for prostate cancer among those prostate-specific antigen value between 2.5 and 4.0 ng/ml

Conditions: Prostate Cancer

Summary: the study aims to evaluate the detection rate and characteristics of prostate cancer among males with psa values between 2.5 and 4.0 ng/ml in nanjing, meanwhile, to access the effectiveness of conducting multi-parametric mri (mpmri) after psa assay.

the investigators are going to collect serum samples and clinical information from men aged ≥50 years in community health service centers in nanjing. the investigators will propose mpmri for those met our criteria of psa values between 2.5 and 4.0 ng/ml. transperineal systematic biopsy and mri/ultrasound fusion targeted biopsy will be offered for those who scored ≥3 points on the prostate imaging-reporting and data system version 2 (pi-rads v2). follow-up examinations annually will be offered for those with a pi-rads score \<3. sequences obtained while conducting mpmri included t2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced using a 3.0-t system.

Eligibility criteria:
inclusion criteria: * age ≥ 50 * psa between 2.5 and 4.0ng/ml * (eastern cooperative oncology group)ecog grade: 0-1 * normal organic function indexes: * (absolute neutrophil count)anc ≧1.5×109/l * (platelet count)plt ≧100×109/l * hb ≧90 g/l * (total bilirubin)tbil ≦1.5×uln * (aspartate aminotransferase)alt≦2.5×uln * (alanine aminotransferase)ast ≦2.5×uln * (blood urea nitrogen)bun (orurea) and cr ≦1.5×uln exclusion criteria: * former serum psa detection * having took proscar in the past 3 months * suffered from any other malignant tumor in the past 5 years * history of acute urinary retention, acute or chronic bacterial or abacterial prostatitis within 6 weeks or other recent infection of the urinary system
comparison of picosecond pulsed nd:yag laser and fractional laser for the treatment of acne scars

Conditions: Acne Scars

Summary: this study compares the application of a picosecond 1064-nm laser with a diffractive lens array with nonablative fractional laser for the treatment of acne scarring.

this trial is a 17-week, prospective, randomized split-face study that compares the results between two facial sides either receiving the picosecond 1064-nm laser or nonablative fractional laser treatment for atrophic acne scar.

Eligibility criteria:
inclusion criteria: * subjects with facial atrophic acne scars * subjects who observe the schedules and protocols of the clinical trial * subjects who give informed consent to participate in the clinical trial exclusion criteria: * subjects who have active acne under treatment * subjects who had received any other treatments for acne scarring for 6 months prior to the first treatment * subjects who underwent other treatments including chemical, mechanical or laser resurfacing during the study period * subjects who have current acute illness * subjects who are considered inappropriate for the clinical trial under the judgement of investigators
smoking, sex hormones, and pregnancy

Conditions: Nicotine Dependence; Contraception

Summary: the investigators aim to (1) examine the association between levels of progesterone (prog), allopregnanolone (allo), and the estradiol/progesterone (e2/p) ratios with smoking-related symptomatology during ad libitum smoking and (2) determine the association between prog, allo, and e2/p with the changes in smoking-related symptomatology and response to nicotine following overnight abstinence

the sample population will consist of oral contraceptive users, both "low" and "high" dose levels of exogenous progesterone with a consistent dose of exogenous estrogen. participants will complete data collection procedures including providing saliva (cortisol to measure stress), urine (cotinine and 3-hydroxycotinine to measure nicotine exposure), and blood (progesterone, allopregnanolone, and estradiol) samples, as well as ecological momentary assessments (ema) daily for seven-days. participants will also complete a 3-hour smoking topography lab session after overnight abstinence and a 4.5-hour nicotine nasal spray lab session after a 14-hour abstinence. these sessions will contain a nicotine challenge via smoking a cigarette or nasal spray with timed-series physiological, subjective, and behavioral responses.

Eligibility criteria:
inclusion criteria: * currently taking oral contraceptives * english fluency * ability to provide informed consent exclusion criteria: * use of progestin only contraceptive * pregnancy
team-based financial incentives for smoking cessation

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to identify the effectiveness of team-base financial incentives for increasing long-term smoking cessation among employees at st. paul's hospital, korea.

about 70% of smokers report that they want to quit, but annually 2 to 3% of smokers succeed. smoking-cessation programs and pharmacologic therapies have been proven effective in helping smokers quit, but only a few smokers are enrolled in those programs. financial incentives may contribute to reinforce smoking cessation among workers through the following pathways: (1) increasing the number of tobacco users who participate in cessation effort; (2) increasing the number of tobacco user who initiate an attempt to quit; and (3) increasing the number of tobacco users who sustain a successful quit effort. moreover, there is a number of advantages to offering smoking cessation support in the workplace, including the accessibility of the target population, the availability of occupational health support and the potential for peer pressure and peer support. in addition, team-based approach for smoking cessation could likely make use of new or existing cessation support resources offered within the workplace. this study is a clinical trial of team-based financial incentives for smoking cessation among a sample of 60 smokers, who are health care workers from st. paul's hospital in korea. smokers will be given a usual care (counseling, education and coverage of prescription drugs) plus a package of financial incentives for self-reported and biochemically validated smoking cessation (urine or saliva cotinine). all incentives will be provided to each team at 6 months post-quit date.

Eligibility criteria:
inclusion criteria: * employees of st. paul's hospital at work sites in korea * current smoker who report having smoked at least 5 cigarettes per day for the prior 12 months * age 18 or older exclusion criteria: * age 17 or younger * unwilling to quit smoking * smoker who does not want to be enrolled in this trial * planning to leave st. paul's hospital within the next 12 months

Keywords: team-based financial incentives smoking cessation
prognostic value of stem cell related markers

Conditions: Breast Cancer

Summary: the goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-ii breast cancer following surgery to remove the tumor.


Eligibility criteria:
inclusion criteria: * ductal carcinoma in situ * dcis + microinvasion stages 1 or 11 without positive lymph nodes exclusion criteria: * tumor specimen with higher than grade ii * braca 1 or braca 2 mutation * neoadjuvant chemotherapy

Keywords: breast cancer stages 0-ii
gut microbiota metagenomics for chronic liver disease

Conditions: Liver Disease Chronic

Summary: gut microbiota modulation has effect on chronic liver disease

chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. it consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma. gut microbiota plays an important roles in the chronic liver disease. it can suppress the progression of the liver disease by moulation gut microbiota. the investigators are still evaluating the effect of gut microbiota on the liver disease.

Eligibility criteria:
inclusion criteria: * age 19+ * normal : ast or alt level \< 50iu/l, bmi \< 25 * liver disease : ast or atl level ≥ 50iu/l, bmi ≥ 25 * patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer) exclusion criteria: * normal : ast or atl level ≥ 50iu/l, bmi ≥ 25 * liver disease : ast or alt level \< 50iu/l, bmi \< 25 * if the patient refuses

Keywords: liver fecal gut microbiota
human papillomavirus in young people epidemiological research 3

Conditions: Human Papillomavirus Infection; HPV; HPV Infection; Anal Cancer; Cancer; Men; HPV 16 Infection

Summary: anal cancer is overrepresented among gay, bisexual and other men who have sex with men (msm), particularly those living with hiv. australia was the first country to introduce a publicly funded national hpv vaccination program in 2007. this program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years. in 2018, the 9-valent vaccine (covering genotypes 6/11/16/18/31/33/45/52/58) replaced the 4-valent vaccine in the national program. the goal of the hyper3 study is to determine the prevalence of anal, genital and oral hpv among 200 young gay and bisexual men aged 16-20 years who were eligible for the school-based 9-valent vaccination. participants will be required to complete a questionnaire and provide samples for hpv testing. no follow-up visits will be required.


Eligibility criteria:
inclusion criteria: * men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024; and men aged 16-20 years in 2025 will be recruited. this is to ensure these men would have been eligible for the 9-valent school-based hpv program) * same-sex attracted * residing in australia since 2018 exclusion criteria: * unable to complete all study requirements in english

Keywords: vaccination vaccine public health prevention men who have sex with men gay and bisexual men immunisation
the effect of solifenacin used for lower urinary tract symptoms on sexual function

Conditions: Urge Incontinence; Urgency-frequency Syndrome

Summary: this study aims to determine whether solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.

solifenacin is an anticholinergic drug that is commonly used for lower urinary tract symptoms such as urgency, frequency and urge urinary incontinence. solifenacin use and sexual function improvement is presented in some research, but the correlation between the improvement in sexual function and luts symptoms is yet not investigated. also the effect on sexual function in premenopausal vs postmenopausal women are unknown.

Eligibility criteria:
inclusion criteria: * women presented in arnavutkoy state hospital gynecology clinic with lower urinary tract symptoms that are planned to start treatment with solifenacin 5 mg (vesicare 5mg). * patients agreed to involve in the study, having discussed other treatment options and possible side effects of the medication. * informed consent obtained exclusion criteria: * urinary tract infection * stress urinary incontinence * urinary retention * grade 2 or above pelvic organ prolapse according to pop-q scale * solifenacin contraindications such as narrow angle glaucoma, allergy of solifenacin or other components of the drug.

Keywords: urgency urge urinary incontinence solifenacin sexual function menopause anticholinergic
non-inferiority clinical trial of dexchlorpheniramine (cream versus gel) in the relief of sunburn related symptoms

Conditions: Sunburn

Summary: topical antihistamines can be used to promote relief of sunburn related symptoms (erythema, itch and burning sensations). dexchlorpheniramine maleate 1% cream is a topical antihistamine formulation approved by anvisa in brazil for the relief of skin irritation and pruritus, including the ones caused by sunburn. the aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% gel) with the standard preparation (1% cream) for the relief of sunburn related symptoms and to demonstrate the safety of both preparations.


Eligibility criteria:
inclusion criteria: * signs of solar erythema of mild to moderate intensity resulting from voluntary exposure to sun within the last 72 hours * compliance of the subject to the treatment protocol * agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old exclusion criteria: * pregnancy or risk of pregnancy * lactation * signs of severe sunburn (vesicles, bullae or ulceration) * use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study * history of atopy or allergic diseases * history of allergy to any component of the formulations * other conditions considered by the investigator as reasonable for non-eligibility

Keywords: sunburn dexchlorpheniramine gel cream
bcl-2 inhibitors combined with azacytidine and chemotherapy in elderly patients with previously untreated aml

Conditions: Acute Myeloid Leukemia

Summary: in this prospective study, 30 newly untreated elderly patients with acute myeloid leukemia(aml) who were not suitable for standard chemotherapy were enrolled to observe the efficacy and side effects of venetoclax (ven) combined with azacytidine (aza) and chemotherapy in newly treated elderly patients with aml. overall survival (os), complete remission rate/complete remission with incomplete recovery of blood cell count (cr/ cri) were used as the primary endpoints, and time to response (ttr), duration of response (dor), mortality, and recurrence rate were used as secondary endpoints,and the incidence of adverse events were evaluated.

induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc. consolidation therapy: regimen a or b was chosen according to the wishes of the patients. in addition, venetoclax was used for 14 days for positive minimal residual disease(mrd) and 7 days for mrd negative. regimen a: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen b: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; if the patient's ecog performance status ≥2, the reduction of regimen ia(cytarabine+idarubicin)was 5+2. maintenance therapy: azacytidine 75mg/m2, d1-7, sc.

Eligibility criteria:
inclusion criteria: 1. the elderly patients(≥ 60) with aml diagnosed according to who criteria; 2. participants are ineligible for induction regimen; 3. the eastern cooperative oncology group (ecog) performance status is 0-3; 4. the patients and their families agree and sign the informed consent form. exclusion criteria: 1. previous treatment for aml (including hypomethylating agents and other chemotherapy drugs); 2. infiltration of the central nervous system; 3. drugs use history affecting cyp3a within 7 days before enrollment; 4. participants considered by the investigator to be unsuitable for inclusion.

Keywords: acute myeloid leukemia bcl-2 inhibitors azacytidine chemotherapy
assessment of pft, safety, and pk of zileuton injection in asthma patients

Conditions: Asthma

Summary: a single intravenous injection of zileuton (150 or 300 mg) will be administered to patients with stable asthma. the goals will be to determine if zileuton i.v. can produce a rapid increase in fev1/pefr and when this effect can be seen. the safety of this route of administration of zileuton will also be studied. pk will be obtained in a population based method.


Eligibility criteria:
inclusion criteria: 1. male or female patients 12 years of age or older 2. diagnosis of asthma by current ats guidelines 3. fev1 of 4-80%. 4. reversibility of at least 13% after bronchodilator treatment 5. must be willing to with hold saba for 6 hours and ics for 24 hours prior to treatment. 6. informed consent exclusion criteria: 1. females of child bearing potential unless using birth control 2. uncontrolled systemic disease 3. known hypersensitivity to zileuton or components of zileuton injection. 4. upper or lower respiratory tract infection within the last 2 weeks 5. admission to hospital or er visit for asthma exacerbation within the last 3 months 6. course of oral or parenteral steroids within the last 3 months 7. current smoker or h/o \> 15 pack years 8. creatinine \> 1.5 x uln 9. alt \> 3 x uln 10. bp \< 100 (systolic) 11. h/o hiv 12. h/o alcohol or drug abuse 13. patients taking xolair, theophylline, montelukast, zafirlukast, nedocromil, cromolyn sodium, zyflo (within the past 7 days), warfarin, propranolol, inhaled anti-cholinergics, or laba. 14. pregnant or breast feeding females 15. current participation or participation in an experimental drug study within 30 days.

Keywords: asthma, exacerbation, pulmonary function
combined treatment of resistant hypertension and atrial fibrillation

Conditions: Hypertension, Resistant to Conventional Therapy; Atrial Fibrillation

Summary: the purpose of this study is the comparative evaluation of systolic blood pressure (sbp) lowering, atrial fibrillation (af) recurrence and clinical data in patients with paroxysmal/persistent af and resistant hypertension, undergoing af ablation alone or combined with percutaneous renal denervation.


Eligibility criteria:
inclusion criteria: * symptomatic drug-refractory af (with history of failure of ≥2 class i or iii antiarrhythmic drugs) in patients referred for catheter ablation of af * paf with ≥1 monthly episodes or persaf in patients who had already undergone ≥3 electrical cardioversions. paf was defined as episodes lasting less than 7 days with spontaneous termination. persaf was defined as lasting more than 7 days before being terminated pharmacologically or by electrical cardioversion. * office-based systolic blood pressure of ≥160 mm hg, despite treatment with ≥3 antihypertensive drugs (including 1 diuretic) * a glomerular filtration rate ≥45 ml/min/1⋅73 m2, with modification of diet using a renal disease formula exclusion criteria: * previous atrial fibrillation ablation * type 1 of diabetes mellitus * structural heart disease * secondary cause of atrial hypertension * severe renal artery stenosis or renal arteries abnormalities * previous operations on renal arteries * pregnancy * previous heart, kidney, liver, or lung transplantation * unwillingness of participant

Keywords: resistant hypertension atrial fibrillation percutaneous renal denervation
hemodynamic change of coronary atherosclerotic plaque after evolocumab treatment

Conditions: Atherosclerosis

Summary: compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. this study is going to investigate the change of lesion-specific hemodynamic significance as determined by ml(machine learning)-based ct-ffr (computed tomography-fractional flow reserve)after evolocumab treatment.


Eligibility criteria:
inclusion criteria: * 1.baseline ccta revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm); * 2.patients were referred for optimal medical treatment; * 3.patients agreed to undergo follow-up ccta at 1-year interval. exclusion criteria: * 1.patients had previous history of myocardial infarction or coronary revascularization; * 2.patients were contraindicated to the usage of iodine contrast media; * 3.image quality of baseline or follow-up ccta was severely impaired (in presence of severe artifact, non-diagnostic); * 4.patients withdrew the informed consents during follow-up; * 5.patients experienced major adverse cardiac events during follow-up; * 6.patients refused to undergo follow-up ccta; * 7.lost follow-up